Intercept raises $25 million
This article was originally published in Scrip
Intercept Pharmaceuticals has raised $25 million in the second tranche of a $41 million financing round, led by Genextra, which began in May 2006. The financing will enable Intercept to complete Phase II clinical trials of its lead compound, the orally available farnesoid X receptor INT-747, of which three are currently underway in patients with primary biliary cirrhosis and diabetic patients with non-alcoholic fatty liver disease. The company said that with the backing of Genextra it will also be able to continue to advance its pipeline of other FXR and TGR5 agonists. In addition to the financing, which exceeded the company's expectations of $20.5 million, Dr Kenneth Noonan, a partner at LEK Consulting, has been appointed non-executive chairman of Intercept's board of directors. He succeeds James Mervis, who remains a director of the company.
You may also be interested in...
Myotec Therapeutics and Hybrid Biosystems are to merge to form PsiOxus Therapeutics with £3.6 million in funding from a syndicate led by the former's previous backer Imperial Innovations.
A Phase II efficacy and safety study of Trophos' cholesterol-oxime compound TRO40303 to treat cardiac ischaemia-reperfusion injury in acute myocardial infarction patients will be substantially underwritten by funds from the European Union, the Marseilles-based company says. Trophos is to head a new 16-partner consortium called MitoCare, a 2.5 year international translational medicine project that has received a €6 million award under the European Union Seventh Framework Programme for research. The project will begin in January 2011.
Alcon's board of directors has finally approved a merger agreement with Novartis for the Alcon shares the latter does not already own, drawing a close to protracted negotiations that first began nearly a year ago.